The Clinical and Economic Benefits of Co-Testing Versus Primary HPV Testing for Cervical Cancer Screening: A Modeling Analysis

Felix Juan C.; Lacey Michael J.; Miller Jeffrey D.; Lenhart Gregory M.; Spitzer Mark; Kulkarni Rucha

首页> 外文期刊>Journal of women’s health >The Clinical and Economic Benefits of Co-Testing Versus Primary HPV Testing for Cervical Cancer Screening: A Modeling Analysis

【24h】

The Clinical and Economic Benefits of Co-Testing Versus Primary HPV Testing for Cervical Cancer Screening: A Modeling Analysis

机译：宫颈癌筛查的共同检测与主要HPV检测的临床和经济效益：模型分析

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: Consensus United States cervical cancer screening guidelines recommend use of combination Pap plus human papillomavirus (HPV) testing for women aged 30 to 65 years. An HPV test was approved by the Food and Drug Administration in 2014 for primary cervical cancer screening in women age 25 years and older. Here, we present the results of clinical-economic comparisons of Pap plus HPV mRNA testing including genotyping for HPV 16/18 (co-testing) versus DNA-based primary HPV testing with HPV 16/18 genotyping and reflex cytology (HPV primary) for cervical cancer screening.

机译：背景：共识性美国宫颈癌筛查指南建议针对30至65岁的女性使用联合Pap联合人乳头瘤病毒（HPV）检测。 2014年，美国食品药品监督管理局（FDA）批准了一项HPV测试，以筛查25岁以上女性的原发性宫颈癌。在这里，我们介绍了Pap和HPV mRNA测试的临床经济比较结果，包括HPV 16/18的基因分型（共同测试）与HPV 16/18基因型和反射细胞学（基于HPV的原代）的基于DNA的主要HPV测试宫颈癌筛查。

著录项

来源
《Journal of women’s health》 |2016年第6期|共11页
作者
Felix Juan C.; Lacey Michael J.; Miller Jeffrey D.; Lenhart Gregory M.; Spitzer Mark; Kulkarni Rucha;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类妇幼卫生;
关键词

相似文献

外文文献
中文文献
专利

1. The Clinical and Economic Benefits of Co-Testing Versus Primary HPV Testing for Cervical Cancer Screening: A Modeling Analysis [J] . Felix Juan C., Lacey Michael J., Miller Jeffrey D., Journal of women’s health . 2016,第6期

机译：宫颈癌筛查的共同检测与主要HPV检测的临床和经济效益：模型分析
2. Capsule Commentary on Jin et. al., Cost-Effectiveness of Primary HPV Testing, Cytology and Co-testing as Cervical Cancer Screening for Women above Age 30 Years [J] . Walsh Judith Journal of general internal medicine . 2016,第11期

机译：金等胶囊评论。等人，作为30岁以上女性宫颈癌筛查的主要HPV检测，细胞学和联合检测的成本-效果
3. Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program [J] . Jie-Bin Lew, Kate T Simms, Megan A Smith, The Lancet Public Health . 2017,第2期

机译：在澳大利亚进行过HPV疫苗接种和未接种疫苗的女性中，主要的HPV检测与基于细胞学的宫颈筛查：国家宫颈癌筛查计划的有效性和经济评估
4. Clinical role of hWAPL in histologic diagnosis of cervical cancer and cervical intraepithelial neoplasia: Correlation with p16INK4a expression and HPV testing [C] . Xie Yonghong, Shen Peng, Chen Linlong, 2011 International Conference on Human Health and Biomedical Engineering . 2011

机译：hWAPL在宫颈癌和宫颈上皮内瘤变的组织学诊断中的临床作用：与p16INK4a表达和HPV检测的相关性
5. Self-administered HPV Testing as a Cervical Cancer Screening Option: Exploring the Perspectives of Hispanic and Arab Women in the United States. [D] . Kidder, Elizabeth O. 2014

机译：自我管理的HPV检测作为宫颈癌筛查的选择：探讨美国西班牙裔和阿拉伯妇女的观点。
6. The Clinical and Economic Benefits of Co-Testing Versus Primary HPV Testing for Cervical Cancer Screening: A Modeling Analysis [O] . Juan C. Felix, Michael J. Lacey, Jeffrey D. Miller, -1

机译：宫颈癌筛查的联合检测与主要HPV检测的临床和经济效益：模型分析
7. The Clinical and Economic Benefits of Co-Testing Versus Primary HPV Testing for Cervical Cancer Screening: A Modeling Analysis [O] . Juan C. Felix, Michael J. Lacey, Jeffrey D. Miller, 2016

机译：共同检测的临床和经济效益与宫颈癌筛查的原发性HPV检测：建模分析

The Clinical and Economic Benefits of Co-Testing Versus Primary HPV Testing for Cervical Cancer Screening: A Modeling Analysis

摘要

著录项

相似文献

相关主题

期刊订阅